Consensus Fulgent Genetics, Inc.

Stocks

FLGT

US3596641098

Healthcare Facilities & Services

Market Closed - Nasdaq 16:00:00 2026-09-23 EDT			5-day change	1st Jan Change
21.27 ^USD	-1.76%		-1.66%	-19.03%

07-30	Fulgent Genetics, Inc., Q2 2026 Earnings Call, Jul 30, 2026
07-30	Tranche Update on Fulgent Genetics, Inc.'s Equity Buyback Plan announced on March 8, 2022.	CI

Evolution of the Average Target: Fulgent Genetics, Inc.

Evolution of the Target Price: Fulgent Genetics, Inc.

Changes in Analyst Recommendations: Fulgent Genetics, Inc.

3997fa418ccc1a029ec32811cc34ec33.3wcmi3aM_TeS_jSg8LWdTNhqe005shT57BziZ97vw0o.tj5B7xfajEfZkVPZxYerPrBfEXV961_UiXTVU5aHpS2xYRC7NPiuVqW8Qw~156e1f35aa08455d70655c2d749dd8eb

Analysts' recommendations: Fulgent Genetics, Inc.

03-02	UBS Adjusts Fulgent Genetics Price Target to $22 From $35, Maintains Buy Rating	MT
25-08-05	UBS Upgrades Fulgent Genetics to Buy From Neutral, Adjusts Price Target to $30 From $20	MT
25-08-01	Fulgent Genetics beats Q2 revenue estimates	RE
25-03-03	UBS Adjusts Fulgent Genetics Price Target to $20 From $27, Maintains Neutral Rating	MT
24-08-05	UBS Adjusts Fulgent Genetics Price Target to $27 From $25, Maintains Neutral Rating	MT
24-03-06	Piper Sandler Adjusts Price Target on Fulgent Genetics to $25 From $28, Maintains Neutral Rating	MT
24-02-29	UBS Adjusts Fulgent Genetics Price Target to $25 From $35, Maintains Neutral Rating	MT
23-12-07	UBS Initiates Coverage on Fulgent Genetics With Neutral Rating, $35 Price Target	MT
23-03-02	Credit Suisse Lowers Fulgent Genetics' Price Target to $45 From $50 After Mixed Q4 Results, Keeps Outperform Rating	MT
22-12-08	Piper Sandler Downgrades Fulgent Genetics to Neutral From Overweight, Adjusts Price Target to $40 From $65	MT
22-11-18	Raymond James Starts Fulgent Genetics at Outperform With $45 Price Target	MT
22-11-14	Piper Sandler Adjusts Price Target on Fulgent Genetics to $65 From $70, Maintains Overweight Rating	MT
22-11-14	Credit Suisse Adjusts Fulgent Genetics' Price Target to $50 From $65, Keeps Outperform Rating	MT
22-08-25	Credit Suisse Initiates Fulgent Genetics at Outperform with $65 Price Target	MT
22-05-16	Piper Sandler Adjusts Fulgent Genetics' Price Target to $70 From $85, Reiterates Overweight Rating	MT
22-05-04	Oppenheimer Adjusts Fulgent Genetics Price Target to $112 From $123, Maintains Outperform Rating	MT
22-03-01	Piper Sandler Adjusts Fulgent Genetics' Price Target to $85 From $80, Reiterates Overweight Rating	MT
22-02-24	Oppenheimer Adjusts Fulgent Genetics Price Target to $123 From $125, Maintains Outperform Rating	MT
22-02-04	Piper Sandler Assumes Fulgent Genetics at Overweight with $80 Price Target	MT
22-01-25	Oppenheimer Adjusts Fulgent Genetics' Price Target to $125 From $141, Maintains Outperform Rating	MT
21-08-10	Fulgent Genetics : Credit Suisse Adjusts Fulgent Genetics' Price Target to $65 from $55, Keeps Underperform Rating	MT
21-08-10	Fulgent Genetics : Oppenheimer Adjusts Fulgent Genetics PT to $141 From $118, Maintains Outperform Rating	MT
21-05-07	Fulgent Genetics : Oppenheimer Adjusts Fulgent Genetics PT to $118 From $126, Maintains Outperform Rating	MT
21-04-07	Fulgent Genetics : Oppenheimer Adjusts Fulgent Genetics PT to $126 From $130 on Q1 Preview, Maintains Outperform Rating	MT
21-03-05	Fulgent Genetics : Piper Sandler Adjusts Price Target on Fulgent Genetics to $140 From $135, Maintains Overweight Rating	MT

More recommendations

Medical & Diagnostic Laboratories

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
FULGENT GENETICS, INC.	-	-	-	-10.67%
NATERA, INC.				-10.94%
LABCORP HOLDINGS INC.				+13.43%
SONIC HEALTHCARE LIMITED				+18.12%
RADNET, INC.				+29.25%
DR. LAL PATHLABS LIMITED				+1.43%
GENEDX HOLDINGS CORP.				+6.16%
NEOGENOMICS, INC.				+7.42%
FLEURY S.A.				-13.07%
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.				+7.28%
Average				+4.84%
Weighted average by Cap.				+0.18%